Drug
Ak120
Ak120: highest development phase Phase 2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK120 NCT06092762 | Phase 2 | Atopic Dermatitis |
Latest
No recent events.
Follow Ak120 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.